Hospital
Saline Hospital LLC
Saline Hospital LLC was paid $7.80M by Medicaid between Jan 2018 and Dec 2024, across 193 billing codes. Its largest line is A0425, Ground mileage, per statute mile — 9.8% of everything it billed.
33Billing provider infoSALINE HOSPITAL LLC
BENTON, AR 72015
BENTON, AR 72015
33aNPI1235111071assigned 11/17/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.80M
24GClaims318,467
24DCodes billed193
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#13 of 49
Median peer was paid$2.62M
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 56,160 | $1.22M | |
| 2019 | 60,338 | $1.51M | |
| 2020 | 42,843 | $1.17M | |
| 2021 | 34,650 | $1.09M | |
| 2022 | 40,128 | $1.12M | |
| 2023 | 47,149 | $998K | |
| 2024incomplete | 37,199 | $705K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| A0425 | Ground mileage, per statute mile | 9.8% | 13,431 | 9,514 | $761K |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 9.5% | 6,401 | 5,155 | $740K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 7.9% | 6,462 | 4,918 | $619K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.2% | 3,566 | 3,092 | $480K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.0% | 4,143 | 3,609 | $387K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 4.1% | 3,316 | 2,605 | $319K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.0% | 3,668 | 2,957 | $310K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.7% | 4,537 | 3,786 | $291K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | 3.0% | 4,275 | 3,050 | $234K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.0% | 1,917 | 1,053 | $232K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.5% | 27,578 | 20,948 | $197K |
| 59025 | Fetal non-stress test | 2.5% | 1,334 | 818 | $192K |
181 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | 2.5% | 14,092 | $192K |
| 80053 | Comprehensive metabolic panel | 2.0% | 11,760 | $155K |
| 99283 | Emergency room visit (moderate) | 1.9% | 2,917 | $150K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.7% | 1,283 | $132K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 1,557 | $112K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 1,398 | $96K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 1,182 | $96K |
| 99284 | Emergency room visit (serious) | 1.2% | 3,120 | $94K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 9,308 | $89K |
| 87634 | <1% | 1,250 | $72K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 778 | $67K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,602 | $67K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,459 | $64K |
| 84703 | <1% | 6,802 | $63K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,740 | $61K |
| 83880 | <1% | 2,510 | $60K | |
| 99285 | Emergency room visit (most serious) | <1% | 2,561 | $55K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,343 | $50K |
| 84484 | <1% | 6,069 | $49K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,162 | $47K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,820 | $47K |
| 83735 | <1% | 8,224 | $46K | |
| 94761 | <1% | 2,023 | $45K | |
| 80061 | Lipid panel | <1% | 2,229 | $37K |
| 83690 | <1% | 5,357 | $37K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 905 | $36K |
| 81001 | <1% | 10,472 | $34K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,672 | $34K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 567 | $33K |
| 84145 | <1% | 2,280 | $33K | |
| 80320 | <1% | 1,969 | $27K | |
| 73630 | <1% | 1,108 | $27K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,185 | $25K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,050 | $25K |
| 86901 | <1% | 1,187 | $25K | |
| 86140 | <1% | 4,299 | $23K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,297 | $22K |
| 73610 | <1% | 1,211 | $22K | |
| 73562 | <1% | 694 | $21K | |
| 87077 | <1% | 2,482 | $20K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 456 | $18K |
| 12001 | <1% | 87 | $18K | |
| 82962 | <1% | 3,251 | $18K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 109 | $17K |
| 73130 | <1% | 726 | $17K | |
| 87088 | <1% | 2,095 | $16K | |
| 94760 | <1% | 1,155 | $16K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,377 | $16K |
| 80076 | <1% | 1,616 | $15K | |
| 73110 | <1% | 630 | $15K | |
| 82565 | <1% | 681 | $14K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 116 | $14K |
| 83605 | <1% | 1,811 | $14K | |
| A0398 | Als routine disposable supplies | <1% | 1,587 | $14K |
| 82550 | <1% | 2,297 | $13K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 299 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 299 | $13K |
| 85610 | <1% | 3,865 | $13K | |
| 87186 | <1% | 2,389 | $13K | |
| 81003 | <1% | 4,935 | $13K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 285 | $12K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,817 | $12K |
| 85730 | <1% | 2,609 | $12K | |
| 76830 | Ultrasound, transvaginal | <1% | 247 | $12K |
| 85379 | <1% | 1,157 | $12K | |
| 82553 | <1% | 1,173 | $11K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 85 | $11K |
| 73030 | <1% | 597 | $11K | |
| 90715 | <1% | 576 | $11K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 358 | $10K |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 184 | $10K |
| 72110 | <1% | 314 | $10K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 293 | $10K |
| 71020 | <1% | 626 | $9K | |
| 84439 | <1% | 883 | $8K | |
| 87807 | <1% | 602 | $7K | |
| 87400 | <1% | 1,243 | $7K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 157 | $7K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 108 | $7K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 62 | $6K |
| 82805 | <1% | 254 | $6K | |
| 87040 | <1% | 646 | $6K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,249 | $5K |
| 86885 | <1% | 479 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,014 | $5K |
| 97161 | <1% | 118 | $5K | |
| 86900 | <1% | 1,188 | $4K | |
| A0422 | Ambulance (als or bls) oxygen and oxygen supplies, life sustaining situation | <1% | 289 | $4K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 37 | $4K |
| 81025 | <1% | 594 | $4K | |
| 70486 | <1% | 31 | $4K | |
| 82150 | <1% | 569 | $4K | |
| 82948 | <1% | 692 | $3K | |
| 80050 | General health panel | <1% | 74 | $3K |
| 80164 | <1% | 235 | $3K | |
| 84702 | <1% | 330 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 753 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 66 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,818 | $3K |
| 12011 | <1% | 13 | $3K | |
| 73502 | <1% | 90 | $2K | |
| 71010 | <1% | 325 | $2K | |
| 72131 | <1% | 29 | $2K | |
| 74018 | <1% | 122 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 103 | $2K |
| 73080 | <1% | 113 | $2K | |
| 80329 | <1% | 159 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,491 | $2K |
| 95811 | <1% | 12 | $2K | |
| 82947 | <1% | 294 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 29 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,898 | $2K |
| 74022 | <1% | 71 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,818 | $2K |
| 96376 | <1% | 32 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 113 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 367 | $1K |
| 87210 | <1% | 252 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,392 | $1K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 30 | $1K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 86 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,676 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,637 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 157 | $1K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 644 | $1K |
| 76642 | <1% | 76 | $1K | |
| 81511 | <1% | 27 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,561 | $1K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 90 | $965.02 |
| 76801 | <1% | 25 | $940.50 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 26 | $928.80 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 339 | $843.06 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 575 | $720.92 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 101 | $666.66 |
| 74019 | <1% | 28 | $661.57 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 655 | $648.11 |
| 73090 | <1% | 40 | $634.29 | |
| 88342 | <1% | 40 | $603.80 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 506 | $594.99 |
| 74230 | <1% | 16 | $582.66 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 22 | $559.52 |
| 82010 | <1% | 93 | $513.21 | |
| 80055 | <1% | 16 | $474.76 | |
| 82728 | <1% | 28 | $408.45 | |
| 93971 | <1% | 12 | $333.72 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 42 | $314.00 |
| 83540 | <1% | 53 | $307.04 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 139 | $286.05 |
| 80178 | <1% | 32 | $285.08 | |
| 86787 | <1% | 15 | $220.80 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 193 | $211.32 |
| 73140 | <1% | 21 | $196.32 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 93 | $173.86 |
| 87070 | <1% | 12 | $158.80 | |
| 86308 | <1% | 25 | $156.37 | |
| 82607 | <1% | 12 | $150.64 | |
| 83615 | <1% | 24 | $142.74 | |
| 82570 | <1% | 20 | $118.24 | |
| G0378 | Hospital observation service, per hour | <1% | 297 | $106.04 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 17 | $102.58 |
| 84156 | <1% | 21 | $89.25 | |
| 85651 | <1% | 26 | $81.12 | |
| 84100 | <1% | 34 | $76.41 | |
| 84550 | <1% | 14 | $71.06 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 182 | $34.57 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 14 | $32.80 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 95 | $30.15 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,477 | $23.47 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 46 | $9.35 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 28 | $8.76 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 29 | $7.78 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 20 | $2.70 |
| J3490 | Unclassified drugs | <1% | 477 | $2.45 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 210 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 17 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 68 | $0.00 |
| A0394 | Als specialized service disposable supplies; iv drug therapy | 0% | 186 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 18 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 26 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 98 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.